{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T04:56:24Z","timestamp":1793336184969,"version":"4.5.0"},"reference-count":171,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,6,1]],"date-time":"2022-06-01T00:00:00Z","timestamp":1654041600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: CardioOncology"],"published-print":{"date-parts":[[2022,6]]},"DOI":"10.1016\/j.jaccao.2022.03.005","type":"journal-article","created":{"date-parts":[[2022,6,21]],"date-time":"2022-06-21T13:58:24Z","timestamp":1655819904000},"page":"149-165","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Cardiometabolic Comorbidities in Cancer\u00a0Survivors"],"prefix":"10.1016","volume":"4","author":[{"given":"Leah L.","family":"Zullig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Sung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel G.","family":"Khouri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shelley","family":"Jazowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nishant P.","family":"Shah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Sitlinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dan V.","family":"Blalock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Colette","family":"Whitney","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Kikuchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hayden B.","family":"Bosworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew J.","family":"Crowley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen M.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Igor","family":"Klem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin C.","family":"Oeffinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan","family":"Dent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.jaccao.2022.03.005_bib1","first-page":"363","article-title":"Cancer treatment and survivorship statistics, 2019","volume":"69","author":"Miller","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib2","doi-asserted-by":"crossref","first-page":"34","DOI":"10.6004\/jnccn.2014.0005","article-title":"Survivorship: introduction and definition. Clinical practice guidelines in oncology","volume":"12","author":"Denlinger","year":"2014","journal-title":"J\u00a0Natl Compr Canc Netw"},{"issue":"4","key":"10.1016\/j.jaccao.2022.03.005_bib3","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1182\/blood-2006-05-022335","article-title":"Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study","volume":"109","author":"Baker","year":"2007","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib4","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s11764-018-0716-6","article-title":"Patterns of medication adherence in a multi-ethnic cohort of prevalent statin users diagnosed with breast, prostate, or colorectal cancer","volume":"12","author":"Banegas","year":"2018","journal-title":"J\u00a0Cancer Surviv"},{"key":"10.1016\/j.jaccao.2022.03.005_bib5","first-page":"29","article-title":"Competing risks of cancer mortality and cardiovascular events in individuals with multimorbidity","volume":"4","author":"Bayliss","year":"2014","journal-title":"J\u00a0Comorb"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib6","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/EDE.0000000000000394","article-title":"Cardiovascular Disease Mortality Among Breast Cancer Survivors","volume":"27","author":"Bradshaw","year":"2016","journal-title":"Epidemiology"},{"issue":"34","key":"10.1016\/j.jaccao.2022.03.005_bib7","doi-asserted-by":"crossref","first-page":"3837","DOI":"10.1200\/JCO.2017.72.4211","article-title":"Preexisting Cardiovascular Risk And Subsequent Heart\u00a0Failure Among Non-Hodgkin Lymphoma Survivors","volume":"35","author":"Salz","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"3","key":"10.1016\/j.jaccao.2022.03.005_bib8","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s10549-017-4282-9","article-title":"Risk of death from cardiovascular disease following breast cancer: a systematic review","volume":"164","author":"Gernaat","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib9","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1007\/s10549-018-4723-0","article-title":"The risk of cardiovascular disease following breast cancer by Framingham risk score","volume":"170","author":"Gernaat","year":"2018","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib10","first-page":"7","article-title":"Cancer statistics, 2019","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"issue":"8","key":"10.1016\/j.jaccao.2022.03.005_bib11","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1200\/JCO.2016.70.5400","article-title":"Prevention and Monitoring Of Cardiac Dysfunction In Survivors Of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline","volume":"35","author":"Armenian","year":"2017","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.jaccao.2022.03.005_bib12","doi-asserted-by":"crossref","first-page":"6084","DOI":"10.1002\/cam4.1886","article-title":"Doxorubicin-induced heart failure in cancer patients: A cohort study based on the Korean National Health Insurance Database","volume":"7","author":"Kim","year":"2018","journal-title":"Cancer Med"},{"issue":"25","key":"10.1016\/j.jaccao.2022.03.005_bib13","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.1200\/JCO.2006.10.4976","article-title":"Congestive heart failure in older women treated with adjuvant anthracycline chemotherapy for breast cancer","volume":"25","author":"Pinder","year":"2007","journal-title":"J\u00a0Clin Oncol"},{"issue":"24","key":"10.1016\/j.jaccao.2022.03.005_bib14","doi-asserted-by":"crossref","first-page":"2504","DOI":"10.1016\/j.jacc.2012.07.068","article-title":"Incidence of heart failure or cardiomyopathy after adjuvant trastuzumab therapy for breast cancer","volume":"60","author":"Chen","year":"2012","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"33","key":"10.1016\/j.jaccao.2022.03.005_bib15","doi-asserted-by":"crossref","first-page":"4222","DOI":"10.1200\/JCO.2013.48.7884","article-title":"Trastuzumab-related cardiotoxicity among older patients with breast cancer","volume":"31","author":"Chavez-MacGregor","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaccao.2022.03.005_bib16","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1038\/s41416-018-0159-x","article-title":"Cardiovascular disease incidence after internal mammary chain irradiation and anthracycline-based chemotherapy for breast cancer","volume":"119","author":"Boekel","year":"2018","journal-title":"Br J Cancer"},{"issue":"11","key":"10.1016\/j.jaccao.2022.03.005_bib17","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa1209825","article-title":"Risk of ischemic heart disease in women after radiotherapy for breast cancer","volume":"368","author":"Darby","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"3","key":"10.1016\/j.jaccao.2022.03.005_bib18","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s10549-017-4133-8","article-title":"Adiposity, post-diagnosis weight change, and risk of cardiovascular events among early-stage breast cancer survivors","volume":"162","author":"Feliciano","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"20","key":"10.1016\/j.jaccao.2022.03.005_bib19","doi-asserted-by":"crossref","first-page":"2530","DOI":"10.1200\/JCO.2011.39.9014","article-title":"Cardiopulmonary function and age-related decline across the breast cancer survivorship continuum","volume":"30","author":"Jones","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaccao.2022.03.005_bib20","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s11764-013-0267-9","article-title":"Cardiovascular risk factors among long-term survivors of breast, prostate, colorectal, and gynecologic cancers: a gap in survivorship care?","volume":"7","author":"Weaver","year":"2013","journal-title":"J\u00a0Cancer Surviv"},{"issue":"7","key":"10.1016\/j.jaccao.2022.03.005_bib21","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1158\/1055-9965.EPI-16-0133","article-title":"Anticipating the \"Silver Tsunami\": Prevalence Trajectories And Comorbidity Burden Among Older Cancer Survivors In The United States","volume":"25","author":"Bluethmann","year":"2016","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"3","key":"10.1016\/j.jaccao.2022.03.005_bib22","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/(SICI)1097-0142(20000201)88:3<653::AID-CNCR24>3.0.CO;2-1","article-title":"Cancer and comorbidity: redefining chronic diseases","volume":"88","author":"Ogle","year":"2000","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib23","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s10549-013-2424-2","article-title":"Changes in adherence to statins and subsequent lipid profiles during and following breast cancer treatment","volume":"138","author":"Calip","year":"2013","journal-title":"Breast Cancer Res Treat"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib24","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1007\/s10549-016-4043-1","article-title":"Characteristics associated with nonadherence to medications for hypertension, diabetes, and dyslipidemia among breast cancer survivors","volume":"161","author":"Calip","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"36","key":"10.1016\/j.jaccao.2022.03.005_bib25","doi-asserted-by":"crossref","first-page":"4458","DOI":"10.1200\/JCO.2012.44.0891","article-title":"Running on empty: cardiovascular reserve capacity and late effects of therapy in cancer survivorship","volume":"30","author":"Koelwyn","year":"2012","journal-title":"J\u00a0Clin Oncol"},{"issue":"2","key":"10.1016\/j.jaccao.2022.03.005_bib26","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.clbc.2018.01.008","article-title":"Prognostic impact of weight change during adjuvant chemotherapy in patients with high-risk early breast cancer: results from the ADEBAR study","volume":"18","author":"Mutschler","year":"2018","journal-title":"Clin Breast Cancer"},{"issue":"23","key":"10.1016\/j.jaccao.2022.03.005_bib27","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1002\/cncr.29488","article-title":"Diet quality of cancer survivors and noncancer individuals: Results from a national survey","volume":"121","author":"Zhang","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jaccao.2022.03.005_bib28","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/s12885-015-1026-2","article-title":"Weight and weight change following breast cancer: evidence from a prospective, population-based, breast cancer cohort study","volume":"15","author":"Vagenas","year":"2015","journal-title":"BMC Cancer"},{"issue":"12","key":"10.1016\/j.jaccao.2022.03.005_bib29","doi-asserted-by":"crossref","first-page":"6331","DOI":"10.1002\/cam4.1847","article-title":"Factors associated with physical inactivity in adult breast cancer survivors-A population-based study","volume":"7","author":"Huneidi","year":"2018","journal-title":"Cancer Med"},{"issue":"21","key":"10.1016\/j.jaccao.2022.03.005_bib30","doi-asserted-by":"crossref","first-page":"3452","DOI":"10.1200\/JCO.2008.20.0923","article-title":"Impact of androgen deprivation therapy on cardiovascular disease and diabetes","volume":"27","author":"Alibhai","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"34","key":"10.1016\/j.jaccao.2022.03.005_bib31","doi-asserted-by":"crossref","first-page":"5537","DOI":"10.1200\/JCO.2008.17.7428","article-title":"Late congestive heart failure after hematopoietic cell transplantation","volume":"26","author":"Armenian","year":"2008","journal-title":"J\u00a0Clin Oncol"},{"issue":"14","key":"10.1016\/j.jaccao.2022.03.005_bib32","doi-asserted-by":"crossref","first-page":"1756","DOI":"10.1182\/bloodadvances.2018019117","article-title":"Prediction of cardiovascular disease among hematopoietic cell transplantation survivors","volume":"2","author":"Armenian","year":"2018","journal-title":"Blood Adv"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib33","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1186\/s12885-019-5493-8","article-title":"Cardiovascular medication use and risks of colon cancer recurrences and additional cancer events: a cohort study","volume":"19","author":"Bowles","year":"2019","journal-title":"BMC Cancer"},{"issue":"30","key":"10.1016\/j.jaccao.2022.03.005_bib34","doi-asserted-by":"crossref","first-page":"3664","DOI":"10.1200\/JCO.2016.67.4473","article-title":"Metabolic dysfunction, obesity, and survival among patients with early-stage colorectal cancer","volume":"34","author":"Feliciano","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.03.005_bib35","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1016\/j.canep.2017.10.009","article-title":"Risk of cardiovascular disease among women with endometrial cancer compared to cancer-free women in the Women\u2019s Health Initiative","volume":"51","author":"Felix","year":"2017","journal-title":"Cancer Epidemiol"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib36","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1093\/jnci\/djp404","article-title":"Diabetes and cardiovascular disease during androgen deprivation therapy: observational study of veterans with prostate cancer","volume":"102","author":"Keating","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"21","key":"10.1016\/j.jaccao.2022.03.005_bib37","doi-asserted-by":"crossref","first-page":"2359","DOI":"10.1001\/jama.2011.1745","article-title":"Association of androgen deprivation therapy with cardiovascular death in patients with prostate cancer: a meta-analysis of randomized trials","volume":"306","author":"Nguyen","year":"2011","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1200\/JOP.2014.003046","article-title":"Changes in medication management after a diagnosis of cancer among Medicare beneficiaries with diabetes","volume":"11","author":"Stuart","year":"2015","journal-title":"J\u00a0Oncol Pract"},{"issue":"8","key":"10.1016\/j.jaccao.2022.03.005_bib39","doi-asserted-by":"crossref","first-page":"e800","DOI":"10.1200\/JOP.2016.011742","article-title":"Nonadherence to oral medications for chronic conditions in breast cancer survivors","volume":"12","author":"Yang","year":"2016","journal-title":"J\u00a0Oncol Pract"},{"issue":"9","key":"10.1016\/j.jaccao.2022.03.005_bib40","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1002\/cncr.28509","article-title":"Annual Report to the Nation on the status of cancer, 1975-2010, featuring prevalence of comorbidity and impact on survival among persons with lung, colorectal, breast, or prostate cancer","volume":"120","author":"Edwards","year":"2014","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.jaccao.2022.03.005_bib41","first-page":"41","article-title":"Cancer, comorbidities, and health-related quality of life of older adults","volume":"29","author":"Smith","year":"2008","journal-title":"Health Care Financ Rev"},{"key":"10.1016\/j.jaccao.2022.03.005_bib42","first-page":"206414","article-title":"Chronic Diseases Among Older Cancer Survivors","volume":"2012","author":"Deckx","year":"2012","journal-title":"J\u00a0Cancer Epidemiol"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib43","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1053\/j.seminoncol.2013.09.004","article-title":"Risk-based health care, the cancer survivor, the oncologist, and the primary care physician","volume":"40","author":"McCabe","year":"2013","journal-title":"Semin Oncol"},{"issue":"32","key":"10.1016\/j.jaccao.2022.03.005_bib44","doi-asserted-by":"crossref","first-page":"5117","DOI":"10.1200\/JCO.2006.07.0474","article-title":"Models for Delivering Survivorship Care","volume":"24","author":"Oeffinger","year":"2006","journal-title":"J\u00a0Clin Oncol"},{"issue":"9","key":"10.1016\/j.jaccao.2022.03.005_bib45","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s11606-009-1058-x","article-title":"The role of primary care physicians in cancer care","volume":"24","author":"Klabunde","year":"2009","journal-title":"J\u00a0Gen Intern Med"},{"issue":"7","key":"10.1016\/j.jaccao.2022.03.005_bib46","first-page":"463","article-title":"Physician roles in the cancer-related follow-up care of cancer survivors","volume":"45","author":"Klabunde","year":"2013","journal-title":"Fam Med"},{"issue":"2","key":"10.1016\/j.jaccao.2022.03.005_bib47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.3747\/co.24.3447","article-title":"The role of family physicians in cancer care: perspectives of primary and specialty care providers","volume":"24","author":"Easley","year":"2017","journal-title":"Curr Oncol"},{"issue":"3","key":"10.1016\/j.jaccao.2022.03.005_bib48","first-page":"363","article-title":"Cardiac disease in childhood cancer survivors: risk prediction, prevention, and surveillance: JACC Cardiooncology State-of-the-Art Review","volume":"2","author":"Leerink","year":"2020","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"issue":"4","key":"10.1016\/j.jaccao.2022.03.005_bib49","first-page":"e29","article-title":"Heart disease and stroke statistics--2015 update: a report from the American Heart Association","volume":"131","author":"Mozaffarian","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.jaccao.2022.03.005_bib50","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.arr.2016.01.007","article-title":"Hypertension and aging","volume":"26","author":"Buford","year":"2016","journal-title":"Ageing Res Rev"},{"issue":"14","key":"10.1016\/j.jaccao.2022.03.005_bib51","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1200\/JCO.2015.65.5845","article-title":"Cardiovascular disease risk profiles in survivors of adolescent and young adult (AYA) cancer: the Kaiser Permanente AYA Cancer Survivors Study","volume":"34","author":"Chao","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"15","key":"10.1016\/j.jaccao.2022.03.005_bib52","doi-asserted-by":"crossref","first-page":"1635","DOI":"10.1200\/JCO.21.01738","article-title":"Risk of cardiometabolic risk factors in women with and without a history of breast cancer: the Pathways Heart Study.","volume":"40","author":"Kwan","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.jaccao.2022.03.005_bib53","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1002\/cncr.33981","article-title":"Chronic comorbid conditions among adult cancer survivors in the United States: results from the National Health Interview Survey, 2002-2018","volume":"128","author":"Jiang","year":"2022","journal-title":"Cancer"},{"issue":"5","key":"10.1016\/j.jaccao.2022.03.005_bib54","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1001\/jama.2013.284427","article-title":"2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8)","volume":"311","author":"James","year":"2014","journal-title":"JAMA"},{"issue":"19","key":"10.1016\/j.jaccao.2022.03.005_bib55","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.jacc.2017.11.006","volume":"71","author":"Whelton","year":"2018","journal-title":"J\u00a0Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib56","doi-asserted-by":"crossref","first-page":"430","DOI":"10.7326\/M16-1785","article-title":"Pharmacologic treatment of hypertension in adults aged 60 years or older to higher versus lower blood pressure targets: A Clinical Practice Guideline from the American College of Physicians and the American Academy of Family Physicians","volume":"166","author":"Qaseem","year":"2017","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib57","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1161\/HYPERTENSIONAHA.120.15026","article-title":"2020 International Society of Hypertension Global Hypertension Practice Guidelines","volume":"75","author":"Unger","year":"2020","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.jaccao.2022.03.005_bib58","first-page":"238","article-title":"Hypertension in cancer patients and survivors: epidemiology, diagnosis, and management","volume":"1","author":"Cohen","year":"2019","journal-title":"J\u00a0Am Coll Cardiol CardioOnc"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib59","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1186\/s40885-019-0116-x","article-title":"Risk of hypertension in cancer patients treated with abiraterone: a meta-analysis","volume":"25","author":"Zhu","year":"2019","journal-title":"Clin Hypertens"},{"key":"10.1016\/j.jaccao.2022.03.005_bib60","doi-asserted-by":"crossref","DOI":"10.1136\/bcr.11.2011.5238","article-title":"Unexpected outcome (positive or negative) including adverse drug reactions: Spironolactone, a possible selective androgen receptor modulator, should be used with caution in patients with metastatic carcinoma of the prostate","volume":"2012","author":"Sundar","year":"2012","journal-title":"BMJ Case Rep"},{"issue":"29","key":"10.1016\/j.jaccao.2022.03.005_bib61","doi-asserted-by":"crossref","first-page":"e560","DOI":"10.1200\/JCO.2010.29.5170","article-title":"Abiraterone acetate is well tolerated without concomitant use of corticosteroids","volume":"28","author":"Attard","year":"2010","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.03.005_bib62","unstructured":"Leuprolide (Lupron) [package insert]. 2014. Accessed May 18, 2022. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2014\/020517s036_019732s041lbl.pdf"},{"issue":"2","key":"10.1016\/j.jaccao.2022.03.005_bib63","first-page":"335","volume":"200","author":"Klotz","year":"2018","journal-title":"J\u00a0Urol"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib64","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clbc.2016.07.003","article-title":"Cardiotoxicity of aromatase inhibitors in breast cancer patients","volume":"17","author":"Foglietta","year":"2017","journal-title":"Clin Breast Cancer"},{"issue":"7","key":"10.1016\/j.jaccao.2022.03.005_bib65","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1161\/CIRCULATIONAHA.119.044750","article-title":"Aromatase Inhibitors and the risk of cardiovascular outcomes in women with breast cancer: a population-based cohort study","volume":"141","author":"Khosrow-Khavar","year":"2020","journal-title":"Circulation"},{"issue":"2","key":"10.1016\/j.jaccao.2022.03.005_bib66","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1007\/s10549-017-4447-6","article-title":"Vascular function in breast cancer survivors on aromatase inhibitors: a pilot study","volume":"166","author":"Blaes","year":"2017","journal-title":"Breast Cancer Res Treat"},{"issue":"12","key":"10.1016\/j.jaccao.2022.03.005_bib67","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1001\/jamaoncol.2016.0429","article-title":"Cardiovascular disease after aromatase inhibitor use","volume":"2","author":"Haque","year":"2016","journal-title":"JAMA Oncol"},{"issue":"9922","key":"10.1016\/j.jaccao.2022.03.005_bib68","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/S0140-6736(13)62292-8","article-title":"Anastrozole for prevention of breast cancer in high-risk postmenopausal women (IBIS-II):an international, double-blind, randomised placebo-controlled trial","volume":"383","author":"Cuzick","year":"2014","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib69","doi-asserted-by":"crossref","first-page":"150","DOI":"10.3324\/haematol.2010.030874","article-title":"Late altered organ function in very long-term survivors after allogeneic hematopoietic stem cell transplantation: a paired comparison with their HLA-identical sibling donor","volume":"96","author":"Rov\u00f3","year":"2011","journal-title":"Haematologica"},{"issue":"23","key":"10.1016\/j.jaccao.2022.03.005_bib70","doi-asserted-by":"crossref","first-page":"4505","DOI":"10.1182\/blood-2012-06-437178","article-title":"Cardiovascular risk factors in hematopoietic cell transplantation survivors: role in development of subsequent cardiovascular disease","volume":"120","author":"Armenian","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.jaccao.2022.03.005_bib71","first-page":"263","article-title":"Hypertension in cancer patients","volume":"38","author":"Mouhayar","year":"2011","journal-title":"Texas Heart Inst J"},{"issue":"7","key":"10.1016\/j.jaccao.2022.03.005_bib72","first-page":"503","article-title":"JNC8 guidelines for the management of hypertension in adults","volume":"90","author":"Armstrong","year":"2014","journal-title":"Am Fam Phys"},{"issue":"9","key":"10.1016\/j.jaccao.2022.03.005_bib73","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1093\/jnci\/djq091","article-title":"Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors","volume":"102","author":"Maitland","year":"2010","journal-title":"J\u00a0Natl Cancer Inst"},{"issue":"36","key":"10.1016\/j.jaccao.2022.03.005_bib74","doi-asserted-by":"crossref","first-page":"2768","DOI":"10.1093\/eurheartj\/ehw211","article-title":"2016 ESC Position Paper on cancer treatments and cardiovascular toxicity developed under the auspices of the ESC Committee for Practice Guidelines: the Task Force for Cancer Treatments and Cardiovascular Toxicity of the European Society of Cardiology (ESC)","volume":"37","author":"Zamorano","year":"2016","journal-title":"Eur Heart J"},{"issue":"3","key":"10.1016\/j.jaccao.2022.03.005_bib75","first-page":"151","article-title":"An algorithm for the management of hypertension in the setting of vascular endothelial growth factor signaling inhibition","volume":"10","author":"Copur","year":"2011","journal-title":"Clin Colorectal Cancer"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib76","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1093\/annonc\/mdm184","article-title":"Hypertension as a predictive factor of Sunitinib activity","volume":"18","author":"Rixe","year":"2007","journal-title":"Ann Oncol"},{"issue":"11","key":"10.1016\/j.jaccao.2022.03.005_bib77","doi-asserted-by":"crossref","first-page":"112911","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"23","key":"10.1016\/j.jaccao.2022.03.005_bib78","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N\u00a0Engl J Med"},{"issue":"36","key":"10.1016\/j.jaccao.2022.03.005_bib79","doi-asserted-by":"crossref","first-page":"6152","DOI":"10.1200\/JCO.2009.22.2273","article-title":"Effective strategies for management of hypertension after vascular endothelial growth factor signaling inhibition therapy: results from a phase II randomized, factorial, double-blind study of Cediranib in patients with advanced solid tumors","volume":"27","author":"Langenberg","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"issue":"10","key":"10.1016\/j.jaccao.2022.03.005_bib80","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1158\/1078-0432.CCR-07-4783","article-title":"Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy","volume":"14","author":"Curwen","year":"2008","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.jaccao.2022.03.005_bib81","doi-asserted-by":"crossref","first-page":"e146","DOI":"10.1161\/CIR.0000000000000485","article-title":"Heart Disease and Stroke Statistics-2017 Update: A Report From the American Heart Association","volume":"135","author":"Benjamin","year":"2017","journal-title":"Circulation"},{"issue":"8","key":"10.1016\/j.jaccao.2022.03.005_bib82","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1177\/2047487320905722","article-title":"Status of dyslipidemia management and statin undertreatment in Korean cancer survivors: a Korean National Health and Nutrition Examination Survey study","volume":"28","author":"Shin","year":"2021","journal-title":"Eur J Prev Cardiol"},{"issue":"10","key":"10.1016\/j.jaccao.2022.03.005_bib83","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1200\/JCO.2015.64.0409","article-title":"Cardiovascular disease among survivors of adult-onset cancer: a community-based retrospective cohort study","volume":"34","author":"Armenian","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"12","key":"10.1016\/j.jaccao.2022.03.005_bib84","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"Silverman","year":"2016","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.jaccao.2022.03.005_bib85","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1056\/NEJMoa065994","article-title":"Long-term follow-up of the West of Scotland Coronary Prevention Study","volume":"357","author":"Ford","year":"2007","journal-title":"N\u00a0Engl J Med"},{"issue":"11","key":"10.1016\/j.jaccao.2022.03.005_bib86","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1161\/CIRCULATIONAHA.115.019014","article-title":"Long-term safety and efficacy of lowering low-density lipoprotein cholesterol with statin therapy: 20-year follow-up of West of Scotland Coronary Prevention Study","volume":"133","author":"Ford","year":"2016","journal-title":"Circulation"},{"issue":"20","key":"10.1016\/j.jaccao.2022.03.005_bib87","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"issue":"46","key":"10.1016\/j.jaccao.2022.03.005_bib88","doi-asserted-by":"crossref","first-page":"6462","DOI":"10.1038\/onc.2017.247","article-title":"Elevated tumor LDLR expression accelerates LDL cholesterol-mediated breast cancer growth in mouse models of hyperlipidemia","volume":"36","author":"Gallagher","year":"2017","journal-title":"Oncogene"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib89","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0039445","article-title":"The importance of LDL and cholesterol metabolism for prostate epithelial cell growth","volume":"7","author":"Murtola","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib90","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1186\/s12885-018-4568-2","article-title":"Impact of pre-diagnostic triglycerides and HDL-cholesterol on breast cancer recurrence and survival by breast cancer subtypes","volume":"18","author":"Lofter\u00f8d","year":"2018","journal-title":"BMC Cancer"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2009.06.022","article-title":"Care of the cancer survivor: metabolic syndrome after hormone-modifying therapy","volume":"123","author":"Redig","year":"2010","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib92","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/hsz-2014-0194","article-title":"Cholesterol lowering: role in cancer prevention and treatment","volume":"396","author":"Murai","year":"2015","journal-title":"Biol Chem"},{"issue":"2","key":"10.1016\/j.jaccao.2022.03.005_bib93","first-page":"219","article-title":"The role of cholesterol metabolism in cancer","volume":"9","author":"Ding","year":"2019","journal-title":"Am J Cancer Res"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib94","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.coph.2012.07.006","article-title":"Cholesterol and prostate cancer","volume":"12","author":"Pelton","year":"2012","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib95","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.ajpath.2010.11.005","article-title":"Role of cholesterol in the development and progression of breast cancer","volume":"178","author":"Llaverias","year":"2011","journal-title":"Am J Pathol"},{"issue":"24","key":"10.1016\/j.jaccao.2022.03.005_bib96","doi-asserted-by":"crossref","first-page":"e285","DOI":"10.1016\/j.jacc.2018.11.003","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA Guideline on the Management of Blood Cholesterol: A Report of the American College of Cardiology\/American Heart Association Task Force on Clinical Practice Guidelines","volume":"73","author":"Grundy","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"10.1016\/j.jaccao.2022.03.005_bib97","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1001\/jama.1981.03310280023021","article-title":"Cancer incidence by levels of cholesterol","volume":"245","author":"Williams","year":"1981","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.jaccao.2022.03.005_bib98","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1001\/jama.1987.03390070063024","article-title":"Serum cholesterol levels and cancer mortality in 361,662 men screened for the Multiple Risk Factor Intervention Trial","volume":"257","author":"Sherwin","year":"1987","journal-title":"JAMA"},{"issue":"15","key":"10.1016\/j.jaccao.2022.03.005_bib99","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1001\/jama.1990.03440150091032","article-title":"Declining serum cholesterol levels prior to diagnosis of colon cancer. A time-trend, case-control study","volume":"263","author":"Winawer","year":"1990","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib100","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1001\/jama.1996.03530250071030","article-title":"Does lowering cholesterol cause cancer?","volume":"275","author":"Dalen","year":"1996","journal-title":"JAMA"},{"issue":"7717","key":"10.1016\/j.jaccao.2022.03.005_bib101","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/S0140-6736(71)90911-1","article-title":"Cancer among men on cholesterol-lowering diets: Experience from five clinical trials","volume":"2","author":"Ederer","year":"1971","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib102","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1001\/jama.295.1.74","article-title":"Statins and cancer risk: a meta-analysis","volume":"295","author":"Dale","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib103","article-title":"Lack of effect of lowering LDL cholesterol on cancer: meta-analysis of individual data from 175,000 people in 27 randomised trials of statin therapy","volume":"7","author":"Emberson","year":"2012","journal-title":"PLoS One"},{"issue":"19","key":"10.1016\/j.jaccao.2022.03.005_bib104","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1056\/NEJMoa1201735","article-title":"Statin use and reduced cancer-related mortality","volume":"367","author":"Nielsen","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"27","key":"10.1016\/j.jaccao.2022.03.005_bib105","doi-asserted-by":"crossref","first-page":"42208","DOI":"10.18632\/oncotarget.9906","article-title":"Long-term statin use in patients with lung cancer and dyslipidemia reduces the risk of death","volume":"7","author":"Huang","year":"2016","journal-title":"Oncotarget"},{"issue":"9346","key":"10.1016\/j.jaccao.2022.03.005_bib106","doi-asserted-by":"crossref","first-page":"1623","DOI":"10.1016\/S0140-6736(02)11600-X","article-title":"Pravastatin in elderly individuals at risk of vascular disease (PROSPER):a randomised controlled trial","volume":"360","author":"Shepherd","year":"2002","journal-title":"Lancet"},{"issue":"14","key":"10.1016\/j.jaccao.2022.03.005_bib107","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators","volume":"335","author":"Sacks","year":"1996","journal-title":"N\u00a0Engl J Med"},{"issue":"8","key":"10.1016\/j.jaccao.2022.03.005_bib108","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1002\/pds.3971","article-title":"Effects of breast cancer on chronic disease medication adherence among older women","volume":"25","author":"Santorelli","year":"2016","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jaccao.2022.03.005_bib109","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1186\/s12944-015-0147-6","article-title":"Intensified low-density lipoprotein-cholesterol target of statin therapy and cancer risk: a meta-analysis","volume":"14","author":"Sun","year":"2015","journal-title":"Lipids Health Dis"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib110","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1053\/j.seminoncol.2013.09.010","article-title":"Cancer survivorship: cardiotoxic therapy in the adult cancer patient; cardiac outcomes with recommendations for patient management","volume":"40","author":"Steingart","year":"2013","journal-title":"Semin Oncol"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib111","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1158\/1055-9965.EPI-10-0988","article-title":"Efficacy of exercise interventions in modulating cancer-related fatigue among adult cancer survivors: a meta-analysis","volume":"20","author":"Brown","year":"2011","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib112","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s13058-018-1066-z","article-title":"Statin drugs to reduce breast cancer recurrence and mortality","volume":"20","author":"Beckwitt","year":"2018","journal-title":"Breast Cancer Res"},{"issue":"7","key":"10.1016\/j.jaccao.2022.03.005_bib113","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1249\/MSS.0b013e3181e0c112","article-title":"American College of Sports Medicine roundtable on exercise guidelines for cancer survivors","volume":"42","author":"Schmitz","year":"2010","journal-title":"Med Sci Sports Exerc"},{"issue":"11","key":"10.1016\/j.jaccao.2022.03.005_bib114","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1249\/01.MSS.0000093622.41587.B6","article-title":"Exercise in cancer survivors: an overview of research","volume":"35","author":"Courneya","year":"2003","journal-title":"Med Sci Sports Exerc"},{"issue":"9","key":"10.1016\/j.jaccao.2022.03.005_bib115","first-page":"CD010192","article-title":"Interventions for promoting habitual exercise in people living with and beyond cancer","volume":"9","author":"Turner","year":"2018","journal-title":"Cochrane Database Syst Rev"},{"key":"10.1016\/j.jaccao.2022.03.005_bib116","series-title":"National Diabetes Statistics Report, 2020","year":"2020"},{"issue":"4","key":"10.1016\/j.jaccao.2022.03.005_bib117","doi-asserted-by":"crossref","first-page":"100218","DOI":"10.1016\/j.esmoop.2021.100218","article-title":"Increased risk of diabetes in cancer survivors: a pooled analysis of 13 population-based cohort studies","volume":"6","author":"Xiao","year":"2021","journal-title":"ESMO Open"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib118","doi-asserted-by":"crossref","first-page":"709","DOI":"10.6004\/jnccn.2020.7653","article-title":"Understanding the prevalence of prediabetes and diabetes in patients with cancer in clinical practice: a real-world cohort study","volume":"19","author":"Ose","year":"2021","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib119","doi-asserted-by":"crossref","DOI":"10.1111\/dme.14538","article-title":"The quality of diabetes care among cancer survivors: a retrospective cohort study","volume":"38","author":"Liang","year":"2021","journal-title":"Diabet Med"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib120","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s12902-019-0377-0","article-title":"The impact of cancer on diabetes outcomes","volume":"19","author":"Arreskov","year":"2019","journal-title":"BMC Endocr Disord"},{"issue":"23","key":"10.1016\/j.jaccao.2022.03.005_bib121","doi-asserted-by":"crossref","first-page":"2754","DOI":"10.1001\/jama.2008.824","article-title":"Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis","volume":"300","author":"Barone","year":"2008","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.jaccao.2022.03.005_bib122","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1007\/s00125-014-3186-z","article-title":"Mortality after cancer among patients with diabetes mellitus: effect of diabetes duration and treatment","volume":"57","author":"Ranc","year":"2014","journal-title":"Diabetologia"},{"issue":"7","key":"10.1016\/j.jaccao.2022.03.005_bib123","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s002770050521","article-title":"Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996","volume":"78","author":"van Spronsen","year":"1999","journal-title":"Ann Hematol"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib124","doi-asserted-by":"crossref","first-page":"23","DOI":"10.3803\/EnM.2017.32.1.23","article-title":"Acute hyperglycemia associated with anti-cancer medication","volume":"32","author":"Hwangbo","year":"2017","journal-title":"Endocrinol Metab (Seoul)"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib125","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1007\/s12020-016-1220-2","article-title":"Prevalence, predictors, and outcomes of steroid-induced hyperglycemia in hospitalized patients with hematologic malignancies","volume":"56","author":"Healy","year":"2017","journal-title":"Endocrine"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib126","doi-asserted-by":"crossref","first-page":"e532","DOI":"10.3747\/co.20.1499","article-title":"Glucocorticoid-induced hyperglycemia is prevalent and unpredictable for patients undergoing cancer therapy: an observational cohort study","volume":"20","author":"Harris","year":"2013","journal-title":"Curr Oncol"},{"issue":"11","key":"10.1016\/j.jaccao.2022.03.005_bib127","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1634\/theoncologist.2015-0519","article-title":"Hyperglycemia associated with targeted oncologic treatment: mechanisms and management","volume":"21","author":"Goldman","year":"2016","journal-title":"Oncologist"},{"issue":"2","key":"10.1016\/j.jaccao.2022.03.005_bib128","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1001\/jamaoncol.2017.3064","article-title":"Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens: a systematic review and meta-analysis","volume":"4","author":"Barroso-Sousa","year":"2018","journal-title":"JAMA Oncol"},{"issue":"9","key":"10.1016\/j.jaccao.2022.03.005_bib129","doi-asserted-by":"crossref","first-page":"3144","DOI":"10.1210\/jc.2018-00728","article-title":"Programmed cell death-1 inhibitor-induced type 1 diabetes mellitus","volume":"103","author":"Clotman","year":"2018","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib130","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2337\/cd18-0105","article-title":"Standards of Medical Care in Diabetes-2019 Abridged for Primary Care Providers","volume":"37","author":"American Diabetes","year":"2019","journal-title":"Clin Diabetes"},{"issue":"8","key":"10.1016\/j.jaccao.2022.03.005_bib131","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1016\/j.annonc.2020.05.001","article-title":"Time course and management of key adverse events during the randomized phase III SOLAR-1 study of PI3K inhibitor alpelisib plus fulvestrant in patients with HR-positive advanced breast cancer","volume":"31","author":"Rugo","year":"2020","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.jaccao.2022.03.005_bib132","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1159\/000495698","article-title":"Diabetes and metabolic syndrome in survivors of childhood cancer","volume":"91","author":"Friedman","year":"2019","journal-title":"Horm Res Paediatr"},{"issue":"4","key":"10.1016\/j.jaccao.2022.03.005_bib133","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1007\/s11764-015-0440-4","article-title":"Comorbid condition care quality in cancer survivors: role of primary care and specialty providers and care coordination","volume":"9","author":"Snyder","year":"2015","journal-title":"J\u00a0Cancer Surviv"},{"issue":"9131","key":"10.1016\/j.jaccao.2022.03.005_bib134","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0140-6736(98)07019-6","article-title":"Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group","volume":"352","year":"1998","journal-title":"Lancet"},{"issue":"24","key":"10.1016\/j.jaccao.2022.03.005_bib135","first-page":"2545","article-title":"Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, et\u00a0al. Effects of intensive glucose lowering in type 2 diabetes","volume":"358","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.jaccao.2022.03.005_bib136","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1056\/NEJMoa0808431","article-title":"Glucose control and vascular complications in veterans with type 2 diabetes","volume":"360","author":"Duckworth","year":"2009","journal-title":"N\u00a0Engl J Med"},{"issue":"24","key":"10.1016\/j.jaccao.2022.03.005_bib137","doi-asserted-by":"crossref","first-page":"2560","DOI":"10.1056\/NEJMoa0802987","article-title":"Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes","volume":"358","author":"Group","year":"2008","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib138","doi-asserted-by":"crossref","first-page":"421","DOI":"10.7326\/0003-4819-141-6-200409210-00007","article-title":"Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus","volume":"141","author":"Selvin","year":"2004","journal-title":"Ann Intern Med"},{"issue":"11","key":"10.1016\/j.jaccao.2022.03.005_bib139","doi-asserted-by":"crossref","first-page":"1528","DOI":"10.7326\/M21-0893","article-title":"Sodium\u2013glucose cotransporter-2 inhibitors versus glucagon-like peptide-1 receptor agonists and the risk for cardiovascular outcomes in routine care patients with diabetes across categories of cardiovascular disease","volume":"174","author":"Patorno","year":"2021","journal-title":"Ann Intern Med"},{"issue":"21","key":"10.1016\/j.jaccao.2022.03.005_bib140","doi-asserted-by":"crossref","first-page":"e997","DOI":"10.1161\/CIR.0000000000000679","article-title":"Cardio-oncology rehabilitation to manage cardiovascular outcomes in cancer patients and survivors: a scientific statement from the American Heart Association","volume":"139","author":"Gilchrist","year":"2019","journal-title":"Circulation"},{"issue":"45","key":"10.1016\/j.jaccao.2022.03.005_bib141","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.15585\/mmwr.mm6645a2","article-title":"CDC grand rounds: improving medication adherence for chronic disease management\u2014innovations and opportunities","volume":"66","author":"Neiman","year":"2017","journal-title":"MMWR Morb Mortal Wkly Rep"},{"key":"10.1016\/j.jaccao.2022.03.005_bib142","doi-asserted-by":"crossref","first-page":"6793","DOI":"10.2147\/CMAR.S191040","article-title":"Cardiovascular disease-related chronic conditions among Veterans Affairs nonmetastatic colorectal cancer survivors: a matched case\u2013control analysis","volume":"11","author":"Zullig","year":"2019","journal-title":"Cancer Manag Res"},{"issue":"10","key":"10.1016\/j.jaccao.2022.03.005_bib143","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.pec.2020.04.006","article-title":"Methodological features of quantitative studies on medication adherence in older patients with chronic morbidity: A systematic review","volume":"103","author":"Granata","year":"2020","journal-title":"Patient Educ Counsel"},{"issue":"5","key":"10.1016\/j.jaccao.2022.03.005_bib144","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1111\/j.1365-2125.2012.04167.x","article-title":"A\u00a0new taxonomy for describing and defining adherence to medications","volume":"73","author":"Vrijens","year":"2012","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.jaccao.2022.03.005_bib145","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/bcp.14172","article-title":"The ABC taxonomy for medication adherence translated into French and German","volume":"86","author":"Haag","year":"2020","journal-title":"Br J Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.jaccao.2022.03.005_bib146","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-013496","article-title":"ESPACOMP Medication Adherence Reporting Guidelines (EMERGE): a reactive-Delphi study protocol","volume":"7","author":"Helmy","year":"2017","journal-title":"BMJ Open"},{"issue":"5","key":"10.1016\/j.jaccao.2022.03.005_bib147","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.jaip.2016.05.019","article-title":"What we mean when we talk about adherence in respiratory medicine","volume":"4","author":"Vrijens","year":"2016","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"key":"10.1016\/j.jaccao.2022.03.005_bib148","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/j.diabres.2018.03.011","article-title":"Impact of cancer diagnosis on persistence of oral antidiabetic drugs","volume":"139","author":"Letinier","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"5","key":"10.1016\/j.jaccao.2022.03.005_bib149","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1007\/s00125-015-3497-8","article-title":"Impact of cancer on adherence to glucose-lowering drug treatment in individuals with diabetes","volume":"58","author":"Zanders","year":"2015","journal-title":"Diabetologia"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib150","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.jgo.2020.04.012","article-title":"Changes in chronic medication adherence in older adults with cancer versus matched cancer-free cohorts","volume":"12","author":"Lund","year":"2021","journal-title":"J\u00a0Geriatr Oncol"},{"issue":"9","key":"10.1016\/j.jaccao.2022.03.005_bib151","doi-asserted-by":"crossref","first-page":"585","DOI":"10.3109\/07357907.2011.616252","article-title":"Reduced risk of breast cancer recurrence in patients using ACE inhibitors, ARBs, and\/or statins","volume":"29","author":"Chae","year":"2011","journal-title":"Cancer Invest"},{"issue":"3","key":"10.1016\/j.jaccao.2022.03.005_bib152","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.ahj.2011.06.007","article-title":"Medication adherence: a call for action","volume":"162","author":"Bosworth","year":"2011","journal-title":"Am Heart J"},{"issue":"6","key":"10.1016\/j.jaccao.2022.03.005_bib153","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1080\/08037051.2020.1822732","article-title":"Response to the editorial: \"the international society of hypertension guidelines 2020 - a new drug treatment recommendation in the wrong direction?\"","volume":"29","author":"Poulter","year":"2020","journal-title":"Blood Press"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib154","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1186\/s12875-021-01569-8","article-title":"Low-touch, team-based care for co-morbidity management in cancer patients: the ONE TEAM randomized controlled trial","volume":"22","author":"Zullig","year":"2021","journal-title":"BMC Fam Pract"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib156","doi-asserted-by":"crossref","first-page":"E3","DOI":"10.1188\/11.CJON.E3-E12","article-title":"Looking beyond recurrence: comorbidities in cancer survivors","volume":"15","author":"Edgington","year":"2011","journal-title":"Clin J Oncol Nurs"},{"issue":"7","key":"10.1016\/j.jaccao.2022.03.005_bib157","first-page":"852","article-title":"Vascular complications of cancer chemotherapy","volume":"32","author":"Cameron","year":"2016","journal-title":"Can J Cardiol"},{"issue":"1","key":"10.1016\/j.jaccao.2022.03.005_bib158","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.clbc.2016.07.003","article-title":"Cardiotoxicity of Aromatase Inhibitors in Breast Cancer Patients","volume":"17","author":"Foglietta","year":"2017","journal-title":"Clin Breast Cancer"},{"issue":"3","key":"10.1016\/j.jaccao.2022.03.005_bib159","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1016\/j.freeradbiomed.2005.03.028","article-title":"Nitric oxide synthase inhibitors in experimental ischemic stroke and their effects on infarct size and cerebral blood flow: a systematic review","volume":"39","author":"Willmot","year":"2005","journal-title":"Free Radic Biol Med"},{"issue":"8","key":"10.1016\/j.jaccao.2022.03.005_bib160","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.8890","article-title":"Cardiovascular adverse events associated with BRAF and MEK inhibitors: a systematic review and meta-analysis","volume":"2","author":"Mincu","year":"2019","journal-title":"JAMA Netw Open"},{"issue":"2","key":"10.1016\/j.jaccao.2022.03.005_bib161","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1056\/NEJMoa1203421","article-title":"Improved survival with MEK inhibition in BRAF-mutated melanoma","volume":"367","author":"Flaherty","year":"2012","journal-title":"N\u00a0Engl J Med"},{"issue":"12","key":"10.1016\/j.jaccao.2022.03.005_bib162","doi-asserted-by":"crossref","first-page":"2932","DOI":"10.1093\/annonc\/mdx514","article-title":"Meta-analysis of individual patient safety data from six randomized, placebo-controlled trials with the antiangiogenic VEGFR2-binding monoclonal antibody ramucirumab","volume":"28","author":"Arnold","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.jaccao.2022.03.005_bib163","unstructured":"National Committee for Quality Assurance (NCQA) Controlling Blood Pressure. Accessed May 18, 2022. https:\/\/www.ncqa.org\/hedis\/measures\/controlling-high-blood-pressure\/"},{"key":"10.1016\/j.jaccao.2022.03.005_bib164","unstructured":"National Committee for Quality Assurance (NCQA) Statin Therapy for Patients With Cardiovascular Disease and Diabetes. Accessed May 18, 2022. https:\/\/www.ncqa.org\/hedis\/measures\/statin-therapy-for-patients-with-cardiovascular-disease-and-diabetes\/"},{"issue":"32","key":"10.1016\/j.jaccao.2022.03.005_bib165","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1200\/JCO.2016.68.0702","article-title":"Everolimus for the treatment of advanced pancreatic neuroendocrine tumors: overall survival and circulating biomarkers from the randomized, phase III RADIANT-3 study","volume":"34","author":"Yao","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.jaccao.2022.03.005_bib166","unstructured":"TORISEL Kit (temsirolimus) [package insert]. Wyeth Pharmaceuticals Inc; 2014."},{"key":"10.1016\/j.jaccao.2022.03.005_bib167","unstructured":"INLYTA\u00ae (axitinib) [package insert]. Pfizer Labs; 2012."},{"issue":"4","key":"10.1016\/j.jaccao.2022.03.005_bib168","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1182\/blood-2016-09-739086","article-title":"Ponatinib efficacy and safety in Philadelphia chromosome\u2013positive leukemia: final 5-year results of the phase 2 PACE trial","volume":"132","author":"Cortes","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.jaccao.2022.03.005_bib169","series-title":"Pazopanib (Votrient)","year":"2009"},{"issue":"4","key":"10.1016\/j.jaccao.2022.03.005_bib170","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1007\/s12012-018-9499-2","article-title":"Fulminant vascular and cardiac toxicity associated with tyrosine kinase inhibitor sorafenib","volume":"19","author":"Sudasena","year":"2019","journal-title":"Cardiovasc Toxicol"},{"key":"10.1016\/j.jaccao.2022.03.005_bib171","series-title":"Sunitinib (Sutent)","year":"2011"},{"key":"10.1016\/j.jaccao.2022.03.005_bib172","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/j.ctrv.2017.07.006","article-title":"Incidence and risk of cardiotoxicity in cancer patients treated with targeted therapies","volume":"59","author":"Santoni","year":"2017","journal-title":"Cancer Treat Rev"}],"container-title":["JACC: CardioOncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322002198?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666087322002198?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T18:55:33Z","timestamp":1762973733000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666087322002198"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,6]]},"references-count":171,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,6]]}},"alternative-id":["S2666087322002198"],"URL":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.03.005","relation":{},"ISSN":["2666-0873"],"issn-type":[{"value":"2666-0873","type":"print"}],"subject":[],"published":{"date-parts":[[2022,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cardiometabolic Comorbidities in Cancer\u00a0Survivors","name":"articletitle","label":"Article Title"},{"value":"JACC: CardioOncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaccao.2022.03.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}]}}